EMERGING THERAPEUTIC OPTIONS FOR PATIENTS WITH CARDIAC AMYLOIDOSIS, EVALUATING THEIR CLINICAL CHARACTERISTICS AND DISCUSSING THE IMPACT OF THESE INTERVENTIONS IN REDUCING THE PROGRESS OF THE DISEASE AND IMPROVING THE QUALITY OF LIFE

• DOI: 10.22533/at.ed.1593572302085

• Palavras-chave: Amyloidosis; Cardiac; Therapy; Quality of life.

• Keywords: Amyloidosis; Cardiac; Therapy; Quality of life.

• Abstract:

  OBJECTIVE: The aim of this study was to identify emerging therapeutic options and the most effective treatments for patients with cardiac amyloidosis, assessing their clinical characteristics and discussing the impact of these interventions on reducing disease progression and improving quality of life. METHODS: A literature review was carried out using the Scielo and PubMed databases. A total of 297 articles were found, from which 18 studies that met the inclusion criteria were selected. RESULTS: Treatment of senile cardiac amyloidosis mainly involves measures to prevent and stop amyloid deposition, taking into account the patient's comorbidities. The importance of early diagnosis and administration of therapy before the condition evolves to significant cardiac dysfunction and other systemic manifestations is highlighted, since treatment is more effective in the early stages of the disease. Treatment is modulated according to risk stratification, aiming to offer greater comfort and survival to the patient, and requires the involvement of a multidisciplinary and competent team. CONCLUSION: The diagnosis of senile cardiac amyloidosis is challenging due to its nonspecific clinical manifestations, which often results in delayed treatment. The main therapeutic approaches have been chemotherapy with melphalan and prednisone, autologous stem cell transplantation (ASCT) and anti-plasma cell therapy in more advanced stages of the disease. With the advancement of therapies, a good prognosis and clinical improvement of patients has been observed.